Cargando…

Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer

Non-small-cell lung cancer (NSCLC) remains by far the major cause of cancer-related death in the Western world in both men and women. The majority of patients will be diagnosed with metastatic disease, and chemotherapy doublets remain the cornerstone of treatment for these patients. However, chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pallis, A G, Fennell, D A, Szutowicz, E, Leighl, N B, Greillier, L, Dziadziuszko, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Minireview
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137421/ https://www.ncbi.nlm.nih.gov/pubmed/21654681 http://dx.doi.org/10.1038/bjc.2011.207

Ejemplares similares

Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004)

Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer
por: Sotelo, Miguel J, et al.
Publicado: (2021)

Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis
por: Lan, Chou-Chin, et al.
Publicado: (2022)

Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer
por: Valenzuela, Guillermo, et al.
Publicado: (2022)

Epidermal growth factor signalling and bone metastasis
por: Lu, X, et al.
Publicado: (2010)

Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth
por: Traish, A M, et al.
Publicado: (2009)

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004)

Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
por: Uramoto, H, et al.
Publicado: (2007)

Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
por: Abunada, Aya, et al.
Publicado: (2023)

Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives
por: Saito, Ayumi, et al.
Publicado: (2021)

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
por: O'Connor, J P B, et al.
Publicado: (2007)

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
por: Barnes, Tristan A., et al.
Publicado: (2017)

Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents
por: Wrona, Anna, et al.
Publicado: (2021)

Neuronal characteristics of small-cell lung cancer
por: Onganer, P U, et al.
Publicado: (2005)

Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
por: Lee, Yong Jun, et al.
Publicado: (2021)

Era of direct acting anti-viral agents for the treatment of hepatitis C
por: Ahmed, Monjur
Publicado: (2018)

The Role of Gut Microbiota in Modulating Tumor Growth and Anticancer Agent Efficacy
por: Kim, Jaeho, et al.
Publicado: (2021)

Progress in immunotherapy for small cell lung cancer
por: Zhao, Dong, et al.
Publicado: (2020)

Vitamin D and calcium signaling in epidermal stem cells and their regeneration
por: Oda, Yuko, et al.
Publicado: (2020)

Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma
por: Alqahtani, Saleh A, et al.
Publicado: (2021)

Risks and benefits of bisphosphonates
por: Coleman, R E
Publicado: (2008)

Treatment options for small cell lung cancer – do we have more choice?
por: Puglisi, M, et al.
Publicado: (2010)

Health benefits of microalgae and their microbiomes
por: Krohn, Ines, et al.
Publicado: (2022)

Stereotactic body radiation therapy for non-small cell lung cancer: A review
por: Prezzano, Kavitha M, et al.
Publicado: (2019)

Progress in treatment of small-cell lung cancer: role of CPT-11
por: Saijo, N
Publicado: (2003)

Current treatment landscape for oligometastatic non-small cell lung cancer
por: Garde-Noguera, Javier, et al.
Publicado: (2022)

Benefits and Costs of Animal Virulence for Microbes
por: Casadevall, Arturo, et al.
Publicado: (2019)

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
por: Aapro, M, et al.
Publicado: (2012)

Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease
por: Kim, Eun Sil, et al.
Publicado: (2023)

Progress in image-guided radiotherapy for the treatment of non-small cell lung cancer
por: Ren, Xiao-Cang, et al.
Publicado: (2019)

Vascular disrupting agents in clinical development
por: Hinnen, P, et al.
Publicado: (2007)

Understanding the benefit of metformin use in cancer treatment
por: Dowling, Ryan JO, et al.
Publicado: (2011)

Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients
por: Pluzanski, Adam, et al.
Publicado: (2020)

Biomarkers of apoptosis
por: Ward, T H, et al.
Publicado: (2008)

Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?
por: Bourke, L, et al.
Publicado: (2013)

Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy
por: Aguado, Carlos, et al.
Publicado: (2022)

Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer
por: Sereno, María, et al.
Publicado: (2021)

Physiological Benefits of Oxygen-Terminating Extracellular Electron Transfer
por: Tokunou, Yoshihide, et al.
Publicado: (2022)

Role of insulin-like growth factor 1 receptor signalling in cancer
por: Larsson, O, et al.
Publicado: (2005)

The U.S. Culture Collection Network Responding to the Requirements of the Nagoya Protocol on Access and Benefit Sharing
por: McCluskey, Kevin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bm1ealsq0gcrp2omc4ik3ps875